Leiden, The Netherlands, March 01, 2018 – DCprime announces today that Erik Manting PhD will become DCprime’s new Chief Executive Officer with immediate effect. Dr Manting succeeds Ada Kruisbeek, who will remain committed to DCprime as Chief Scientific Officer. Prior to joining DCprime, Erik spent 15 years in different management and commercial roles, of which the last 5 years as Executive Director at Kempen & Co, an Amsterdam-based investment bank specialized in Life Sciences and Healthcare. Erik has already spent several months at DCprime from October 2017, as a strategy and business development consultant. Erik Manting possesses an MSc in Medical Biology and a PhD in Molecular Microbiology.
Ada Kruisbeek, CSO and departing CEO commented: “In the past few years, the importance of the immune system in combating cancer has been confirmed again and again. At DCprime, we have documented through both clinical and pre-clinical studies how our cancer vaccine formulations can make a significant contribution to the field. I am particularly happy that Erik Manting, who will be my successor as CEO, is a person who not only brings a strong business and financial track record in the life sciences to the company, but fully appreciates DCprime’s strategy in the immunotherapy field.”
Erik Manting, new CEO of DCprime added: “DCprime has tremendous potential and it is with pleasure that I accept the task of leading the next phase of its growth and development. There is a clear medical need for safe and effective cancer vaccines and this realization drives the DCprime team. I look forward to continue to work with the team on DCprime’s operational progress and the expansion of our network of collaborations. Finally, I would like to thank Ada Kruisbeek for her accomplishments in her role as CEO/CSO and her continued contribution as CSO, which is based on a long professional career dedicated to immuno-oncology.”
About DCprime
DCprime is a privately owned, clinical stage biotechnology company focused on cancer immunotherapies. Founded in 2005, DCprime currently develops cell based cancer vaccines based on its proprietary technology platform DCOne®, with lead DCOne® asset DCP-001 being studied in patients with acute myeloid leukemia (AML). A completed Phase I study has demonstrated that DCP-001 is generally safe and capable of inducing a broad immune response. DCprime has received orphan drug designation from the European Medicines Agency for DCP-001 in AML and has commenced a multi-centre Phase II trial. DCprime intends to develop DCOne® based vaccines in other cancer indications, including multiple myeloma and solid tumours. For more information, visit www.dcprime.com.